Shanghai ChemPartner and SKK collaborate in diabetic research
Shanghai ChemPartner, a group company of ShangPharma, and Sanwa Kagaku Kenkyusho (SKK), a pharmaceutical wholesaler headquartered in Nagoya, Japan, have formed a partnership that will enable SKK to target the Asian market, expand its diabetic research and achieve its drug discovery goals.
Shanghai ChemPartner, a group company of ShangPharma, and Sanwa Kagaku Kenkyusho (SKK), a pharmaceutical wholesaler headquartered in Nagoya, Japan, have formed a partnership that will enable SKK to target the Asian market, expand its diabetic research and achieve its drug discovery goals.
Michael Hui, chief executive of ChemPartner, said: ‘We are proud and honoured that SKK have selected ChemPartner to be one of its partners and we look forward to building a long and successful relationship between our two companies in the future.’ The terms and details of the project were not disclosed.
SKK, a subsidiary of Suzuken, one of the leading pharmaceutical wholesalers in Japan, is a fully-integrated pharmaceutical company with established therapeutic and diagnostic products focusing on diabetes, cardiovascular and inflammation.
Founded in 2003, Shanghai ChemPartner is a global contract research organisation providing chemistry, biology, pharmacology, DMPK, process r&d, analytical development, pre-formulation and contract manufacturing services to pharmaceutical and biotech companies around the world.